Indeed, a causal role of IL-1β in NSCLC has been implicated from a phase III clinical trial showing that treatment with canakinumab, a human monoclonal antibody specific for IL-1β, reduced NSCLC incidence and lung cancer mortality in a dose-dependent manner (15). This evidence concerns the gene IL1B and lung carcinoma.